Home
FDMT
FDMT News

Latest 4D Molecular Therapeutics Inc. (FDMT) News on September 15, 2025

4DMT Announces New Employment Inducement Grants

GlobeNewswire

2 days ago

4DMT Announces New Employment Inducement Grants

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

4DMT to Participate in Upcoming Investor Conferences

Spotlight On 3 Penny Stocks With Market Caps Under $500M

Simply Wall St.

4 months ago

Spotlight On 3 Penny Stocks With Market Caps Under $500M

4DMT Announces New Employment Inducement Grants

GlobeNewswire

4 months ago

4DMT Announces New Employment Inducement Grants

MT Newswires

4 months ago

Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating

MT Newswires

4 months ago

RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Zacks

4 months ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire

4 months ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

4DMT to Participate in Upcoming Investor Conferences

FDA awards RMAT status to 4DMT diabetic macular oedema therapy

Pharmaceutical Technology

4 months ago

FDA awards RMAT status to 4DMT diabetic macular oedema therapy

MT Newswires

4 months ago

4D Molecular's Macular Edema Treatment Gets Regenerative Medicine Designation from FDA

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

GlobeNewswire

4 months ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Discover Fractyl Health And 2 More Promising Penny Stocks

Simply Wall St.

5 months ago

Discover Fractyl Health And 2 More Promising Penny Stocks

4DMT Announces New Employment Inducement Grants

GlobeNewswire

5 months ago

4DMT Announces New Employment Inducement Grants

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

5 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

GlobeNewswire

6 months ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

4D Molecular price target lowered to $35 from $39 at RBC Capital

TipRanks

6 months ago

4D Molecular price target lowered to $35 from $39 at RBC Capital

MT Newswires

6 months ago

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating

MT Newswires

6 months ago

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

6 months ago

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire

7 months ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Spotlight On February 2025's Promising Penny Stocks

Simply Wall St.

7 months ago

Spotlight On February 2025's Promising Penny Stocks

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire

7 months ago

4DMT to Participate in Upcoming Investor Conferences

MT Newswires

7 months ago

Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

GlobeNewswire

7 months ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

GlobeNewswire

8 months ago

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

Top US Penny Stocks To Watch In January 2025

Simply Wall St.

8 months ago

Top US Penny Stocks To Watch In January 2025

MT Newswires

8 months ago

BMO Capital Downgrades 4D Molecular Therapeutics to Market Perform From Outperform, Adjusts Price Target to $15 From $40

MT Newswires

8 months ago

4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

GlobeNewswire

8 months ago

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

GlobeNewswire

8 months ago

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

GlobeNewswire

9 months ago

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now

Insider Monkey

10 months ago

4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

GlobeNewswire

10 months ago

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

MT Newswires

10 months ago

RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

Zacks

10 months ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire

10 months ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely

Simply Wall St.

a year ago

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

Zacks

a year ago

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

GlobeNewswire

a year ago

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

MT Newswires

a year ago

Cantor Fitzgerald Downgrades 4D Molecular Therapeutics to Neutral From Overweight

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate

Benzinga

a year ago

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate

4D Molecular data ‘bode well’ for eye gene therapy, but shares fall

BioPharma Dive

a year ago

4D Molecular data ‘bode well’ for eye gene therapy, but shares fall

MT Newswires

a year ago

Chardan Lifts Price Target on 4D Molecular Therapeutics to $39 From $38, Keeps Buy Rating

MT Newswires

a year ago

4D Molecular Therapeutics Reveals 'Robust, Durable Clinical Activity' in Wet AMD Drug Trial

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

GlobeNewswire

a year ago

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

4DMT Announces Presentations at Upcoming Retina Conferences

GlobeNewswire

a year ago

4DMT Announces Presentations at Upcoming Retina Conferences

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

GlobeNewswire

a year ago

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

GlobeNewswire

a year ago

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire

a year ago

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire

a year ago

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

GlobeNewswire

a year ago

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

MT Newswires

a year ago

BMO Capital Cuts 4D Molecular Therapeutics Price Target to $40 From $63, Maintains Outperform Rating

MT Newswires

a year ago

Sector Update: Health Care Stocks Lean Lower Premarket Wednesday

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

4D Molecular Therapeutics' Phase 2 Trial Shows 4D-150 Therapy Effective in Treating Wet Age-Related Macular Degeneration

GlobeNewswire

a year ago

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

MT Newswires

a year ago

4d Molecular Therapeutics Insider Sold Shares Worth $290,598, According to a Recent SEC Filing

4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?

Zacks

a year ago

4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?

4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock?

Insider Monkey

a year ago

4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock?

MT Newswires

a year ago

4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

GlobeNewswire

a year ago

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

GlobeNewswire

a year ago

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

CNW Group

a year ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

PR Newswire

a year ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

Business Wire

a year ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts

AFP

a year ago

New Zealand scraps plan to tax livestock burps, farts

Business Wire

a year ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

The Wall Street Journal

a year ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool

Bloomberg

a year ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Simply Wall St.

a year ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

GlobeNewswire

a year ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

GlobeNewswire

a year ago

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

GlobeNewswire

a year ago

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

4DMT to Participate in Upcoming Investor Conferences

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

GlobeNewswire

a year ago

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow

Simply Wall St.

a year ago

We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow

4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

Simply Wall St.

a year ago

4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

GuruFocus.com

a year ago

4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire

a year ago

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

4DMT to Participate in Upcoming Investor Conference

GlobeNewswire

a year ago

4DMT to Participate in Upcoming Investor Conference

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks

a year ago

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

4DMT Announces Presentations at ARVO 2024 Annual Meeting

GlobeNewswire

a year ago

4DMT Announces Presentations at ARVO 2024 Annual Meeting

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares

GuruFocus.com

a year ago

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares

4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares

GuruFocus.com

a year ago

4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

GlobeNewswire

a year ago

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

2 years ago

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

2 years ago

4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations

GuruFocus.com

2 years ago

4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

Zacks

2 years ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

GlobeNewswire

2 years ago

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?

Zacks

2 years ago

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

GlobeNewswire

2 years ago

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth

Simply Wall St.

2 years ago

Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth

Share on Social Networks: